Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 5INDUSTRY 3NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Melanoma 8Carcinoma, Non-Small-Cell Lung 8Carcinoma, Hepatocellular 8Squamous Cell Carcinoma of Head and Neck 6Small Cell Lung Carcinoma 5Neoplasms 4Lung Neoplasms 4Prostatic Neoplasms 3Diabetes Mellitus, Insulin-Dependent, 12 3Colorectal Neoplasms 3Carcinoma, Renal Cell 3Advanced Solid Tumors 3Urinary Bladder Neoplasms 2Recurrence 2Lymphoma, Large B-Cell, Diffuse 2Liver Neoplasms 2Head and Neck Neoplasms 2Biliary Tract Neoplasms 2Urothelial Cancer 1Unresectable Hepatocellular Carcinoma 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Tumor 1Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma 1Peritoneal Neoplasms 1Part A and B: Advanced Solid Malignancies 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Non Small Cell Lung Cancer NSCLC 1Non - Small Cell Lung Cancer NSCLC 1

Interventions

Ipilimumab 9pembrolizumab 6Nivolumab 4tremelimumab 3Paclitaxel 3Carboplatin 3spartalizumab 2lenvatinib 2durvalumab 2Doxorubicin 2Bevacizumab 2trastuzumab deruxtecan 1tilsotolimod 1tebentafusp 1osimertinib 1eribulin 1envafolimab 1cemiplimab 1balstilimab 1Vemurafenib 1Vascular Endothelial Growth Factor A 1Standard of Care 1Pemetrexed 1Oxaliplatin 1Docetaxel 1Cisplatin 1Capecitabine 1Axitinib 1Antibodies, Bispecific 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Diabetes Mellitus, Insulin-Dependent, 12 × tremelimumab × Clear all
NCT01843374 2026-03-05

Tremelimumab

MedImmune LLC

Phase 2 Active not recruiting
571 enrolled 19 charts
Other solid neoplasmThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Mesothelioma, Malignant

NCT03084471 2022-12-22

STRONG

AstraZeneca

Phase 3 Completed
867 enrolled 10 charts

Diabetes Mellitus, Insulin-Dependent, 12

NCT02705482 2019-08-26

A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors

MedImmune LLC

Phase 1 Completed
58 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡